Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radotinib in Ph+ Chronic Phase Chronic Myeloid Leukemia Patients With Failure or Intolerance to Previous TKIs Therapy Including Imatinib
NCT03459534Phase 3Recruiting
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Jun 2018
- Primary completion
- Jun 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 3 trial of radotinib in chronic myeloid leukemia (CML), sponsored by Il-Yang Pharmaceutical. Started Jun 2018; status: recruiting.
02
Drugs
radotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03459534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03459534.